Preparation and stability of voriconazole eye drop solution

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 798-799

  Dupuis, Antoine ^a,b   Tournier, Nicolas ^a   Le Moal, Gwenaël ^a   Venisse, Nicolas ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG FORMULATION; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KERATOMYCOSIS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; OPHTHALMIC SOLUTIONS; PYRIMIDINES; TRIAZOLES;

EID: 59749088785     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01126-08     Document Type: Article

References (14)

1. Bourlais, C. L., L. Acar, H. Zia, P. A. Sado, T. Needham, and R. Leverge. 1998. Ophthalmic drug delivery systems - recent advances. Prog. Retin. Eye Res. 17:33-58.
2. Bunya, V. Y., K. M. Hammersmith, C. J. Rapuano, B. D. Ayres, and E. J. Cohen. 2007. Topical and oral voriconazole in the treatment of fungal keratitis. Am. J. Ophthalmol. 143:151-153.
3. Chédru-Legros, V., M. Fines-Guyon, A. Chérel, A. Perdriel, F. Albessard, D. Debruyne, and F. Mouriaux. 2007. Fortified antibiotic (vancomycin, amikacin and ceftazidime) eye drop stability assessment at -20 degrees C. J. Fr. Ophtalmol. 30:807-813.
4. Díaz-Valle, D., J. M. Benitez del Castillo, E. Amor, N. Toledano, M. M. Carretero, and T. Díaz-Valle. 2002. Severe keratomycosis secondary to Sce-dosporium apiospermum. Cornea 21:516-518.
5. Gage, R., and D. A. Stopher. 1998. A rapid HPLC assay for voriconazole in human plasma. J. Pharm. Biomed. Anal. 17:1449-1453.
6. Hernández Prats, C., F. Llinares Tello, A. Burgos San José, J. Selva Otaolaurruchi, and J. P. Ordovás Baines. 2004. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann. Pharmacother. 38:414-417.
7. Lai, T. F., R. Malhotra, R. Esmail-Zaden, A. Galanopoulas, M. Chehade, and D. Selva. 2003. Use of voriconazole in Scedosporium apiospermum keratitis. Cornea 22:391-392.
8. Lau, D., M. Fedinands, L. Leung, R. Fullinfaw, D. Kong, G. Davies, and M. Daniell. 2008. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study. Arch. Ophthalmol. 126:343-346.
9. Mehta, H., H. B. Mehta, P. Garg, and H. Kodial. 2008. Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis. Indian J. Ophthalmol. 56:238-240.
10. Scott, L. J., and D. Simpson. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298.
11. Thiel, M. A., A. S. Zinkernagel, J. Burhenne, C. Kaufmann, and W. E. Haefeli. 2007. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob. Agents Chemother. 51:239-244.
12. Trissel, L. A. 1983. Avoiding common flaws in stability and compatibility studies of injectable drugs. Am. J. Hosp. Pharm. 40:1159-1160.
13. U.S. Pharmacopeial Convention. 1995. Pharmacopeia of the United States of America (the national formulary). U.S. Pharmacopeial Convention, Rockville, MD.
14. Wu, Z., H. Ying, S. Yiu, J. Irvine, and R. Smith. 2002. Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea 21:519-523.